
Daily Derm Times: May 27, 2025
Key Takeaways
- Chronic hand eczema lacks FDA-approved treatments, significantly impacting patients' quality of life and necessitating improved therapeutic options.
- Nemolizumab's approval for atopic dermatitis follows positive outcomes from the ARCADIA studies, marking a significant advancement in treatment.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
POLL: Are You Seeing the Effects of Federal Research Changes?
Answer our poll below.
The Complex Clinical Landscape of Chronic Hand Eczema
Christopher G. Bunick, MD, PhD, presents the significant challenges of CHE due to a lack of FDA-approved treatments, impacting patients' quality of life and requiring better therapeutic options.
Road to RAD: Nemolizumab for AD
Jonathan Silverberg, MD, PhD, MPH, discusses the results of the recent ARCADIA studies, which ultimately led to the approval of nemolizumab for atopic dermatitis.
Dermalyser Secures CE Mark in Europe for AI-Powered Melanoma Detection Tool
AI Medical Technology launches Dermalyser, an AI tool for melanoma diagnosis, enhancing detection accuracy and skin cancer care in Europe.
Microneedling Outperforms Injections in Melasma PRP Study
Microneedling proves more effective than microinjections for PRP therapy in treating melasma, enhancing patient outcomes and satisfaction.
From Patient to President: Amanda Caldwell, MSN, APRN-C, And Her Journey with SDNP
Amanda Caldwell, MSN, APRN-C, is promoting accessibility, education, and relatability as the newly inducted president of the Society for Dermatology Nurse Practitioners.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















